Fitch Affirms Life Technologies Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed its 'BBB' issuer default rating with a stable outlook on Life Technologies.

The New York-based ratings firm said that the rating is supported by a general declining trend in Life Tech's debt leverage over the past three years. It noted that the reduction in leverage is due to a combination of stable operating performance and use of cash for debt reduction.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.